DCPH News and Press, Deciphera Pharmaceuticals Inc. From 11/10/20

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17 at 9:40 AM ET. A live webcast of the event will be available on the &#...

Deciphera Pharmaceuticals, Inc. (DCPH) Q3 2020 Earnings Conference Call November 05, 2020, 04:30 PM ET Company Participants Jen Robinson - VP, IR Steve Hoerter - President and CEO Dan Martin - CCO Matt Sherman - CMO Tucker Kelly - CFO Conference Call Participants Jessica Fye - JP Morgan Allis...

Image source: The Motley Fool. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q3 2020 Earnings Call Nov 6, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Deciphera Pharmaceuticals, Inc. (DCPH) Q3 2020 Earnings Call...

Medison Pharma announces an exclusive distribution agreement with Deciphera Pharmaceuticals (DCPH) to commercialize QINLOCK, a switch-control tyrosine kinase inhibitor, in Canada and Israel for the treatment of fourth-line gastrointestinal stromal tumor ((GIST)), a cancer that occurs in the g...

Deciphera Pharmaceuticals (DCPH): Q3 GAAP EPS of -$1.13 beats by $0.18.Revenue of $15.45M beats by $8.87M.Press Release For further details see: Deciphera Pharmaceuticals EPS beats by $0.18, beats on revenue

– U.S. QINLOCK® Net Revenue of $14.7 Million in the First Full Quarter of Launch – – Marketing Authorisation Application for QINLOCK in Fourth-line GIST Validated by the European Medicines Agency; Commercial Planning for Europe Underway – ...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020. In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 ...

Deciphera Pharmaceuticals (NASDAQ: DCPH ) has announced nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors (GIST) and intra-patient dose escalation data from the ongoing P...

- Strength of QINLOCK PFS and OS Benefit in INVICTUS Study Reinforced with Longer Follow-up Period - - QINLOCK Dose Escalation Upon Progression Offers Additional Clinically Meaningful PFS Benefit in Phase 1 Study - Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the...

Deciphera Pharmaceuticals (NASDAQ: DCPH ) announces data from the ovarian cancer cohort in Part 2 of the ongoing Phase 1b/2 study of rebastinib , the selective TIE2 inhibitor, in combination with paclitaxel and from Part 1 of the Phase 1b/2 study of rebastinib in combination with carbop...